title: Receptor-binding domain as a target for developing SARS vaccines.
abstract: A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.
authors: Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;
authors: Xiaojie
authors: X
authors: Zhu
authors: Qi
authors: Q
authors: Liu
authors: Lanying
authors: L
authors: Du
authors: Lu
authors: L
authors: Lu
authors: Shibo
authors: S
authors: Jiang
keywords: Virus; receptor-binding domain (RBD); severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV); spike protein; vaccine
references: Virology. 2005 Mar 30;334(1):74-82
references: 15749124
references: J Virol. 2005 Sep;79(18):11638-46
references: 16140741
references: J Virol. 2011 Dec;85(23):12201-15
references: 21937658
references: EMBO J. 2005 Apr 20;24(8):1634-43
references: 15791205
references: Hong Kong Med J. 2012 Feb;18 Suppl 2:31-6
references: 22311359
references: Biochem Biophys Res Commun. 2009 Jul 10;384(4):486-90
references: 19422787
references: Virology. 2007 May 10;361(2):304-15
references: 17210170
references: J Infect. 2013 Oct;67(4):348-50
references: 23685240
references: J Immunol. 2008 Jan 15;180(2):948-56
references: 18178835
references: J Virol. 2004 Jun;78(11):5642-50
references: 15140961
references: Vaccine. 2008 Mar 20;26(13):1644-51
references: 18289745
references: N Engl J Med. 2013 May 16;368(20):1888-97
references: 23577628
references: Viral Immunol. 2010 Apr;23(2):211-9
references: 20374001
references: Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64
references: 16339739
references: Microbes Infect. 2013 Jun;15(6-7):432-9
references: 23628410
references: N Engl J Med. 2012 Nov 8;367(19):1814-20
references: 23075143
references: Nat Rev Microbiol. 2009 Mar;7(3):226-36
references: 19198616
references: J Biol Chem. 2004 Jan 30;279(5):3197-201
references: 14670965
references: Nature. 2003 Nov 27;426(6965):450-4
references: 14647384
references: Nature. 2012 Oct 4;490(7418):20
references: 23038444
references: J Infect. 2013 May;66(5):464-6
references: 23266463
references: Virology. 2006 Sep 15;353(1):6-16
references: 16793110
references: Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64
references: 14651994
references: Future Virol. 2013 Jan;8(1):1-2
references: 32201503
references: N Engl J Med. 2013 Jun 13;368(24):2277-85
references: 23697469
references: J Infect. 2013 Aug;67(2):130-40
references: 23583636
references: Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81
references: 16081529
references: Expert Rev Vaccines. 2012 Dec;11(12):1405-13
references: 23252385
references: J Biol Chem. 2004 Nov 19;279(47):49414-9
references: 15345712
references: Vaccine. 2007 Apr 12;25(15):2832-8
references: 17092615
references: Cell Res. 2008 Feb;18(2):290-301
references: 18227861
references: Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81
references: 15474494
references: PLoS Med. 2006 Dec;3(12):e525
references: 17194199
references: Lancet. 2003 Oct 25;362(9393):1353-8
references: 14585636
references: Lancet. 2004 Mar 20;363(9413):938-47
references: 15043961
references: PLoS One. 2012;7(4):e35421
references: 22536382
references: Science. 2005 Sep 16;309(5742):1864-8
references: 16166518
references: Emerg Infect Dis. 2004 Oct;10(10):1774-81
references: 15504263
references: J Immunol. 2005 Apr 15;174(8):4908-15
references: 15814718
references: J Biol Chem. 2005 Aug 19;280(33):29588-95
references: 15980414
references: Nature. 2013 Mar 14;495(7440):176-7
references: 23486053
references: Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52
references: 15530413
references: J Immunol. 2008 Nov 1;181(9):6337-48
references: 18941225
references: Lancet. 2003 Apr 19;361(9366):1319-25
references: 12711465